Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
June 01 2020 - 06:00AM
Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a
leader in cell therapy to treat cancer, today announced that it
intends to offer and sell 12,500,000 American Depositary Shares
(“ADSs”) in an underwritten public offering. The offering is
subject to market conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering. Adaptimmune also expects to grant
the underwriters a 30-day option to purchase additional ADSs at the
public offering price. All of the ADSs in the offering are to be
sold by Adaptimmune, with net proceeds to be used to advance the
development of Adaptimmune’s immunotherapies into and through
clinical trials as well as for other general corporate purposes.
Cowen and SVB Leerink are acting as joint book-running managers
for the offering and Roth Capital Partners is acting as lead
manager for the offering.
A shelf registration statement on Form S-3 relating to the
public offering of the ADSs described above was declared effective
by the Securities and Exchange Commission (“SEC”) on September 10,
2019. The offering is being made only by means of a written
prospectus and prospectus supplement that form a part of the
registration statement. A preliminary prospectus supplement
relating to and describing the terms of the offering will be filed
with the SEC and will be available on the SEC’s web site at
www.sec.gov. When available, copies of the preliminary prospectus
supplement relating to these securities may also be obtained by
sending a request to: Cowen and Company, LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717,
Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926; or SVB Leerink LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA 02110, by telephone at
(800) 808-7525, ext. 6218, or by
emailing syndicate@svbleerink.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of these securities, nor will
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale is not
permitted.
For readers in the European Economic Area and the United
Kingdom
In any EEA Member State and the United Kingdom (each, a
“Relevant State”), this communication is only addressed to and
directed at qualified investors in that Relevant State within the
meaning of the Prospectus Regulation. The term “Prospectus
Regulation” means Regulation (EU) 2017/1129.
For readers in the United Kingdom
This communication, in so far as it constitutes an invitation or
inducement to enter into investment activity (within the meaning of
s21 Financial Services and Markets Act 2000 as amended) in
connection with the securities which are the subject of the
offering described in this press release or otherwise, is being
directed only at (i) persons who are outside the United Kingdom or
(ii) persons who have professional experience in matters relating
to investments who fall within Article 19(5) (Investment
professionals) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the “Order”) or (iii) certain
high value persons and entities who fall within Article 49(2)(a) to
(d) (High net worth companies, unincorporated associations etc) of
the Order; or (iv) any other person to whom it may lawfully be
communicated (all such persons in (i) to (iv) together being
referred to as “relevant persons”). The ADSs are only available to,
and any invitation, offer or agreement to subscribe, purchase or
otherwise acquire such ADSs will be engaged in only with, relevant
persons. Any person who is not a relevant person should not act or
rely on this communication or any of its contents.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company
focused on the development of novel cancer immunotherapy products
for people with cancer. The Company’s unique SPEAR® (Specific
Peptide Enhanced Affinity Receptor) T-cell platform enables the
engineering of T-cells to target and destroy cancer across multiple
solid tumors.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA). These forward-looking statements involve certain risks and
uncertainties. Such risks and uncertainties could cause our actual
results to differ materially from those indicated by such
forward-looking statements, and include, without limitation: the
success, cost and timing of our product development activities and
clinical trials and our ability to successfully advance our TCR
therapeutic candidates through the regulatory and commercialization
processes. For a further description of the risks and uncertainties
that could cause our actual results to differ materially from those
expressed in these forward-looking statements, as well as risks
relating to our business in general, we refer you to our Quarterly
Report on Form 10-Q filed with the SEC on May 14, 2020, and our
other SEC filings. The forward-looking statements contained in this
press release speak only as of the date the statements were made
and we do not undertake any obligation to update such
forward-looking statements to reflect subsequent events or
circumstances.
Adaptimmune Contacts:
Media Relations:
Sébastien Desprez — VP, Communications and Investor RelationsT:
+44 1235 430 583M: +44 7718 453
176Sebastien.Desprez@adaptimmune.com
Investor Relations:
Juli P. Miller, Ph.D. — Senior Director, Investor RelationsT: +1
215 825 9310M: +1 215 460 8920Juli.Miller@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2023 to Mar 2024